
Johnson & Johnson (NYSE:JNJ) Enrols 45,000 Subjects in the Study of Its Experimental COVID-19 Vaccine Candidate
Johnson & Johnson (NYSE:JNJ) has said that it enrolled around 45,000 participants for its late stage study of its single-dose COVID-19 vaccine candidate and anticipates













